3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
150
Carboplatin
110
Cisplatin
95
Bevacizumab
42
Topotecan
39
Gemcitabine
38
liposomal doxorubicin
34
Radiotherapy
29
Doxorubicin
27
Brachytherapy
26
Taxes
24
pembrolizumab
20
olaparib
20
Drug Therapy
20
Hyperthermic Intraperitoneal Chemotherapy
16
Chemotherapy, Adjuvant
16
human papillomavirus vaccine, L1 type 16, 18
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Docetaxel
13
Neoadjuvant Therapy
12
Platinum
10
niraparib
9
Radiation
9
1,2-diaminocyclohexaneplatinum II citrate
9
Vaccines, Synthetic
8
Surgical Procedures, Operative
8
atezolizumab
7
Specimen Handling
7
Papillomavirus Vaccines
7
Letrozole
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Technetium-99
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled